A practical reference on glucagon receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-08-14 and is reviewed periodically as new material appears.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
Development has progressed through early- and mid-stage human studies in adults with obesity and with type 2 diabetes. Published phase 2 data reported reductions in body weight and improvements in glycemic markers over the treatment period. No regulatory agency has approved the compound for any indication, and it remains available only within controlled research settings. Whether benefits observed in trials translate into durable outcomes after treatment stops is not yet established.
Several questions remain unresolved. It is not yet known whether the compound reduces cardiovascular events or mortality, because outcome studies require long follow-up. The durability of weight reduction after treatment withdrawal is uncertain, and rebound has been observed with other incretin-based therapies. Long-term safety data covering several years are limited. Effects in adolescents, in pregnancy, and in people with significant kidney or liver impairment have not been characterized in published reports.
Randomized studies of retatrutide measure change in body weight as a percentage of baseline, along with absolute weight loss. Glycemic endpoints include hemoglobin A1c and fasting plasma glucose. Investigators also track blood pressure, lipid fractions, and liver fat content to characterize effects beyond weight alone. Trial designs typically use double-blind, placebo-controlled groups with periodic dose escalation, and they record adverse events throughout both treatment and follow-up periods.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Not a small molecule |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist activity |
| Appearance | White to off-white powder | Lyophilized solid |
| Solubility | Soluble in water | Also in aqueous buffers |
| Storage | −20 °C or below | Protect from light and moisture |
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Trial reports for this compound rely on a small set of repeated measures. Body weight is normally expressed as percent change from baseline at a fixed week, with absolute kilograms given secondarily. Glycemic endpoints include HbA1c, fasting glucose, and, in some protocols, continuous glucose monitoring summaries. Imaging endpoints such as MRI-derived proton density fat fraction quantify liver fat. Standardization matters because a percent change and a categorical responder analysis can tell different stories about the same dataset.
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
A 2017 study in The BMJ by Tim Dyson and Valeria Cetorelli concluded that "Saddam Hussein's government successfully manipulated the 1999 survey in order to convey a very false impression." In the case of Cuba, a declassified 1960 U.S. State Department memorandum by diplomat Lester D. Mallory argued that "every possible means should be undertaken promptly to weaken the economic life of Cuba" by denying money and supplies in order "to bring about hunger, desperation and overthrow of government." A 2025 study funded by the Center for Economic and Policy Research, authored by Mark Weisbrot, Francisco Rodríguez, and Silvio Rendón and published in The Lancet, estimated that unilateral sanctions by all parties—including those of the United States, United Nations, and European Union—were associated with as many as 564,258 deaths annually between 1971 and 2021. The study found "significant causal association between sanctions and increased mortality" with "the strongest effects for unilateral, economic, and US sanctions." Writing in Al Jazeera about this study, Jason Hickel, Dylan Sullivan, and Omer Tayyab estimated that unilateral sanctions imposed by the United States and European Union since 1970 were associated with approximately 38 million deaths worldwide, with more than half of the victims being children and the elderly, and that sanctions kill several times more people each year than die as direct casualties of war.
=== Cleansing === Cleansing is the process of removing dirt, oil, makeup, and other impurities from the skin. Lathering cleansers, a common type of facial cleanser, generate lather when used, thanks to a surfactant level greater than the CMC (critical micelle concentration). These cleansers contain surfactants with short hydrophobic chains, enabling faster and higher levels of lather. Most lathering cleansers on the market use synthetic surfactants designed to be mild to the skin, reducing skin damage compared to naturally derived surfactants. However, they may be less effective at removing oil-soluble makeup. Liquid lathering cleansers clean through the chemical process of emulsification, suspending or emulsifying dirt and oils, thus allowing them to be removed from the skin during the rinse process. Exfoliating cleansers are used to cleanse and exfoliate the skin twice per day, in the morning and evening. There also exist soapless or "no-rinse" cleansers (syndets).
Recipe Unlimited (previously known as Cara Operations) operates Harvey's, Swiss Chalet, Montana's Cookhouse, Kelsey's Neighbourhood Bar & Grill and other brands. The company also provides catering services to airlines. The revenue for its 1200 restaurants and its airline solutions division in 2008 was over $2 billion. Cara Airline Solutions operated about 10 flight kitchens across Canada that served more than 50 air carriers and rail travel customers, it was sold to Gategroup in 2010. Montana's Cookhouse started in 1995, was acquired by Cara in 2002, and operates 90 restaurants across Canada. There are 200 Swiss Chalet restaurants in Canada and the US. New York Fries is another Recipe Unlimited brand with about 200 stores in Canada, Hong Kong, UAE, Kuwait, and South Korea. New York Fries also had a burger company called South St. Burger, that sells burgers along with New York Fries and other products. It was spun off into a separate entity as part of the Cara acquisition. The largest Canadian-established hamburger chain in the nation, Harvey's was founded in Richmond Hill, Ontario, in 1959, it has franchises from Vancouver to St. John's, though most its restaurants are concentrated in southern Ontario and southern Quebec. On March 31, 2016, Cara announced that it would acquire the St-Hubert chain of rotisserie chicken restaurants in the summer of 2016. Recipe Unlimited also owns Prime Restaurants, the parent company of the restaurant chains East Side Mario's, Casey's, Pat and Mario's, Fionn MacCool's and Bier Markt Esplanade. Co-founded in Sudbury in 1980 by Bernard C.
Its mainland is about 290 kilometres (180 mi) long and 110 kilometres (68 mi) wide. It is the least populated and least densely populated country in Central America. Its population growth rate of 1.87% per year (2018 estimate) is the second-highest in the region and one of the highest in the Western Hemisphere. Its capital is Belmopan, and its largest city is the namesake city, Belize City. The country has a diverse society composed of various cultures and languages. It is the only Central American country where English is the official language, while Belizean Creole, Spanish, and the Mayan languages are widely spoken. Over half the population is multilingual due to the diverse linguistic backgrounds of the population. It is known for its September Celebrations and punta music.
=== Corticosteroids === Corticosteroid injections may provide temporary alleviation of symptoms, although they are not clearly better than a placebo. This form of treatment is thought to reduce discomfort in those with CTS due to its ability to decrease median nerve swelling. The use of ultrasound while performing the injection is more expensive but leads to faster resolution of CTS symptoms. The injections are done under local anesthesia. This treatment is not appropriate for extended periods, however. In general, local steroid injections are used until more definitive treatment options can be used. Corticosteroid injections do not appear to slow disease progression.
Sources: en.wikipedia.org
=== Networking === Service Improvement Plan, a former program to provide a defined level of basic telephone service to all Canadians Standard Interchange Protocol, in library systems System Information Packet, in the DMX512 standard for stage lighting control Session Initiation Protocol, a signaling protocol most commonly used in Internet Telephony
=== Availability === Phenibut is approved in Russia, Ukraine, Belarus, Georgia and Latvia for medical use. It is not approved or available as a medication in other countries in the European Union, the United States, or Australia. In countries where phenibut is not a licensed pharmaceutical drug, it is sold online without a prescription as a "nutritional supplement". It is often used as a form of self-medication for social anxiety.
== Medical uses == Olipudase alfa is indicated as an enzyme replacement therapy for the treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency in people with type A/B or type B. Olipudase alfa is an enzyme replacement therapy, developed to replace patients' deficient or defective enzyme, acid sphingomyelinase, and thereby reduce fat accumulation within cells and relieve some of the symptoms of the disease. Xenpozyme was approved by the European Medicines Agency for the treatment of acid sphingomyelinase deficiency type A/B or type B, and by the US FDA for the treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency.
=== Monitoring and mapping === There are multiple national and international monitoring programs for drug-resistant threats, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant S. aureus (VRSA), extended spectrum beta-lactamase (ESBL) producing Enterobacterales, vancomycin-resistant Enterococcus (VRE), and multidrug-resistant Acinetobacter baumannii (MRAB). ResistanceOpen is an online global map of antimicrobial resistance developed by HealthMap which displays aggregated data on antimicrobial resistance from publicly available and user submitted data. The website can display data for a 25 miles (40 km) radius from a location. Users may submit data from antibiograms for individual hospitals or laboratories. European data is from the EARS-Net (European Antimicrobial Resistance Surveillance Network), part of the ECDC. ResistanceMap is a website by the Center for Disease Dynamics, Economics & Policy and provides data on antimicrobial resistance on a global level. The WHO's AMR global action plan also recommends antimicrobial resistance surveillance in animals. Initial steps in the EU for establishing the veterinary counterpart EARS-Vet (EARS-Net for veterinary medicine) have been made. AMR data from pets in particular is scarce, but needed to support antibiotic stewardship in veterinary medicine. By comparison, there is a lack of national and international monitoring programs for antifungal resistance.
Sources: en.wikipedia.org
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.
Earlier incretin therapies engage one or two receptors. Retatrutide adds glucagon receptor activity, which may raise energy expenditure. Whether this produces larger clinical benefits is still being tested.
It has completed phase 2 trials and moved into later-stage evaluation. No regulator has granted approval. Access outside research settings is not authorized.
Trials measure percentage change in body weight, absolute weight loss, and glycemic markers such as hemoglobin A1c. They also record blood pressure, lipids, and liver fat. Adverse events are tracked throughout.